Vedanta Biosciences, Cambridge, MA
VE707 is a new treatment modality with broad-spectrum of activity being developed for carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL) and vancomycin-resistant Enterococci intestinal decolonization as an infection control strategy for highly susceptible patient populations, including ICU, dialysis, hematopoietic stem cell (HSCT) and solid organ transplant (SOT) patients. If successful, VE707 could serve as a catalyst for the restoration of a healthy microbiota, spare future antibiotic usage, slow the development of antibiotic resistance and limit the dissemination of multi-drug-resistant organisms (MDRO). CRE, ESBL, and VRE infections are some of the most common hospital-acquired infections and are estimated to affect over 500,000 intensive care unit, dialysis, solid organ transplant, and hematopoietic stem cell transplant patients each year in the U.S. and Europe.
Current Development Stage: Preclinical
CARB-X Investment: Initial investment of up to $5.8m with a potential option payments up to $3.5m
Initial CARB-X Investment Date: August 1, 2019